DIRS.INFO The most relevant business & tech news

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

☆ McKinsey advised drug companies on how to 'turbocharge' opioid sales. Now it's under criminal investigation.
▼ + stars: | 2024-04-25 | by ( Meghan Morris | ) www.businessinsider.com time to read: +3 min

The Department of Justice is investigating McKinsey for advising opioid producers on boosting sales. The firm previously paid nearly $1 billion to resolve lawsuits related to its opioid work. The investigation is also looking at potential obstruction of justice by McKinsey and its employees. News of the investigation underscores how McKinsey's opioid work — which the firm said it stopped in 2019 — continues to plague the consultancy. In a 2018 email, for example, a since-fired McKinsey executive wrote to another senior executive about the firm's legal risk.

Persons: —, Endo, Martin Elling Organizations: Justice, McKinsey, Service, McKinsey & Company, US Department of Justice, Street, Purdue Pharma, DOJ, of, Purdue Locations: Virginia, Western, of Virginia, of Massachusetts, Seattle

☆ I quit medicine for an entry-level corporate job. I felt behind but didn't have the passion to become a low-paid doctor.
▼ + stars: | 2024-04-25 | by ( Charissa Cheong | ) www.businessinsider.com time to read: +7 min

Salaha Ashraf spent her last few years of medical school feeling stressed and anxious. Ashraf went to medical school in 2014 but pivoted into a corporate career after deciding she didn't want to be a doctor. I felt more passionate about business management after one year compared to four years of medical school. I don't wish I was a doctorI try to look back at medical school in a positive light. If I felt empowered to follow my passion, maybe I would have studied psychology, which I found interesting at school.

Persons: Salaha Ashraf, —, Ashraf, I've, I'd Organizations: Service, NHS, Business Locations: Bolton, England

☆ Stocks making the biggest moves midday: Meta, Victoria's Secret, Microsoft, Caterpillar and more
▼ + stars: | 2024-04-25 | by ( Pia Singh | ) www.cnbc.com time to read: +5 min

Honeywell posted adjusted earnings per share of $2.25, beating analysts' estimates of $2.17 per share, per LSEG. Revenue for the quarter also came in better-than-expected at $9.11 billion, compared to the $9.03 billion analysts were expecting. ServiceNow — The digital workflow firm slid 5% after it only narrowly beat analysts' revenue expectations in the first quarter. ServiceNow posted revenue of $2.6 billion, slightly higher than the $2.59 billion analysts polled by LSEG had anticipated. Caterpillar — Shares tumbled 6.5% after revenues of $15.8 billion for the most recent quarter missed analysts' estimates of $16.04 billion, according to LSEG.

Persons: Goldman Sachs, Mark Zuckerberg, ServiceNow, LSEG, —, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Pia Singh, Michelle Fox Organizations: Facebook, Meta, Tech, Microsoft, Beverage, JPMorgan, Monster Beverage, Honeywell —, Honeywell, Revenue, Merck, Co, LSEG, — Bank of America, Southwest Airlines —, Management, StreetAccount, Machines, IBM, Bank of America, Caterpillar, Nvidia —, Nvidia, Comcast, Deutsche Bank — U.S, Deutsche Bank, CNBC Locations: NBCUniversal

☆ 'Ozempic face' could create a huge market for fillers. One newly-public company wants to cash in.
▼ + stars: | 2024-04-25 | by ( Geoff Weiss | Julia Pugachevsky | ) www.businessinsider.com time to read: +1 min

Its CEO told Bloomberg that weight-loss drugs could boost its fillers business. Ozempic face is a result of aging and rapid weight loss, one cosmetic dermatologist said. NEW LOOK Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. AdvertisementThe CEO of Swiss pharmaceutical giant Galderma thinks the popularity of weight-loss drugs like Ozempic could boost its facial fillers business. That's because Ozempic can result in a sunken-in look in some patients' faces, Galderma CEO Flemming Ornskov told Bloomberg — an effect he said fillers can help counteract.

Persons: —, Flemming Ornskov, Flemming Organizations: Swiss pharma, Bloomberg, Service, Business Locations: Swiss

☆ Audacious Ukrainian drone attacks keep doing massive damage to Russia's oil industry
▼ + stars: | 2024-04-25 | by ( Tom Porter | ) www.businessinsider.com time to read: +3 min

The strikes are doing serious damage to Russia's oil and gas sector. Bloomberg reported that Russia's oil refining is at an 11 month low. AdvertisementBloomberg earlier this week reported that Russia's oil refining is at an 11-month low because of flooding and Ukraine's drone campaign. Ukraine's attacks on Russian oil depots are one of the few bright spots in its war in recent months. "Future Ukrainian drone strikes may disable and disrupt more of Russia's refining capacity and inflict critical constraints on Russian refining that begin to substantially impact Russia's production of distillate products," the analysts said.

Persons: —, Joe Biden's Organizations: Bloomberg, Service, AFP, Metallurgical, The Locations: Ukraine, Russia, Russia's Smolensk, Lipetsk, Russia's, Ukraine's, US

☆ Stocks making the biggest moves premarket: Meta Platforms, Honeywell, Merck, Southwest Airlines and more
▼ + stars: | 2024-04-25 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

However, first-quarter earnings and revenue both came above analysts' estimates. Honeywell — The industrial stock rose 2.2% in premarket trading after the company posted earnings per share of $2.25, beating LSEG analysts' estimates of $2.17. Revenue for the quarter came in at $9.11 billion, compared to the $9.03 billion analysts were expecting. Analysts surveyed by LSEG forecast $1.88 in earnings per share and $15.20 billion in revenue. ServiceNow — The workflow management company shed 4% after narrowly beating analysts' revenue expectations in the first quarter.

Persons: Merck, LSEG, ServiceNow, —, Macheel, Samantha Subin, Jesse Pound, Pia Singh, Alex Harring Organizations: Facebook, Honeywell, Merck, Southwest Airlines, American Airlines, LSEG, StreetAccount, IBM, Caterpillar, Deutsche Bank — U.S, Deutsche Bank, Comcast, Technology, Revenue, CNBC Locations: NBCUniversal

☆ Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 billion. That outlook includes a one-time charge of roughly 26 cents per share related to Merck's acquisition of Harpoon Therapeutics in January. Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.

Persons: Merck Organizations: Merck, Harpoon Therapeutics, LSEG Locations: Rahway , New Jersey, U.S

☆ Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
▼ + stars: | 2024-04-24 | by ( Ryan Anastasio | ) www.cnbc.com time to read: +2 min

The U.S. Senate has launched an investigation into the high price of Novo Nordisk 's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States. "As important as these drugs are, they will not do any good for the millions of patients who cannot afford them," wrote Sanders. Wegovy, which is even more expensive than Ozempic, is subject to similarly disparate pricing overseas, wrote Sanders. The powerful progressive senator also made a simple request of the drug company CEO: "Will Novo Nordisk substantially reduce both the list price and the net price of both Ozempic and Wegovy?" He gave Novo Nordisk until May 8 to answer a series of questions about the drug's pricing.

Persons: Ozempic, Danish drugmaker, Sen, Bernie Sanders, Sanders, Lars Fruergaard Jørgensen, Jørgensen Organizations: U.S . Senate, Novo Nordisk, Vermont Independent, Health, Education, Labor, Pensions, Nordisk Locations: United States, Danish, Vermont, Canada, Germany

The Justice Department is investigating McKinsey & Company, the international consulting giant, for its role in helping drug companies maximize their sale of opioids. Since 2021, McKinsey has agreed to pay about $1 billion to settle investigations and lawsuits across the United States related to the firm’s work with opioid makers, principally Purdue Pharma, the maker of OxyContin. McKinsey recommended that Purdue “turbocharge” its sales of the drug in the midst of the opioid crisis, which has killed hundreds of thousands of Americans. News of the criminal investigation was first reported by The Wall Street Journal on Wednesday. Last year another opioid maker, Mallinckrodt, said it received a grand jury subpoena from the same U.S. attorney’s office but did not mention any connection to McKinsey.

Persons: Endo, Mallinckrodt Organizations: McKinsey & Company, U.S, Western, of, McKinsey, Purdue Pharma, Purdue “ turbocharge, Wall, The New York Times Locations: Massachusetts, of Virginia, Washington, United States

☆ Not all dividend strategies are the same. How to choose the best one for you
▼ + stars: | 2024-04-24 | by ( Michelle Fox | ) www.cnbc.com time to read: +6 min

She considers herself a dividend income investor, looking for names that provide a healthy payout for her clients. Her portfolio typically generates a 5% dividend yield or better. Honeywell has a 6% five-year annual dividend growth rate, he said. Lastly, CME Group not only has a 2.2% dividend yield, it tends to pay a special dividend once a year that's posted strong growth, he said. CME has five-year annual dividend growth of 15%, and a flawless balance sheet, he said.

Persons: Jenny Harrington, Kevin Simpson, Harrington, Simpson, Stocks, Kinder Morgan, Richard Kinder Organizations: Asset Management, Wealth, Merck, Verizon, SEC, Companies, Honeywell International, CME Group, Honeywell, Boeing, Group Locations: United States

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Broadcom : Broadcom's AI business, which includes co-designing custom chips for tech giants such as Club holding Alphabet, is booming. The newspaper reported April 12 that Salesforce was in talks to buy Informatica, which sent the Club holding's shares plunging. Wells Fargo : Another trim is due for our Wells Fargo position after a great run for the bank stock, Jim argued. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jim, Johnson, Abbott, Andy Jassy, Bausch, Salesforce, Salesforce didn't, Tom Jorden, We've, It's, Walt Disney, Nelson Peltz's, Bob Iger's, Estee Lauder, there's, Eaton, We're, he's, Locker, he'd, Vimal Kapur, Linde, Eli Lilly, Eli Lilly's, TikTok, Joe Biden, Morgan Stanley, Morgan Stanley's, Ted Pick, Jensen Huang, Nikesh Arora, haven't, Laxman Narasimhan, Sands, Stanley Black, Decker, TJ Maxx, TJX, Wells, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Johnson, Web Services, Broadcom, VMWare, GE Healthcare, GE, Bausch Health, Costco Wholesale, Costco, Street, Informatica, Coterra, DuPont De Nemours, DuPont, Walt, Disney, Ford, GM, Philips, Siemens, Google, Honeywell, Linde, Facebook, Meta, Microsoft, Nvidia, Investors, AMD, Oregon State University, Palo Alto Networks, UnitedHealth, Procter & Gamble, Constellation Brands, Constellation, Modelo, TJX, Marshalls, Home Goods, Wynn Resorts, Jim Cramer's Charitable, New York Stock Exchange, Afp, Getty Locations: China, Informatica, Ford, Estee, U.S, mater, Palo, Corona, Wells Fargo, Wells, Macao, New York City

☆ When Tesla shares rise — these 7 stocks have tended to rise too, according to recent history
▼ + stars: | 2024-04-24 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Seven stocks in the S & P 500 tend to rise alongside Tesla shares, according to an analysis of recent data by CNBC Pro . The share price performances of these S & P 500 stocks were highly correlated to Tesla's last month. However, unlike Tesla's more than 30% plunge this year, these stocks have either remained flat or have relatively modest negative returns. A correlation of zero would indicate no statistical link between the EV automaker's stock and the share price of the seven companies. The consensus upside potential for the stocks listed above was derived from FactSet's poll of analysts covering each stock.

Persons: Elon Musk, weathers, — CNBC's Lora Kolodny Organizations: CNBC Pro, Juniper Networks, Seagate Technology, Tyler Technologies, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, IDEXX Laboratories, EV, CNBC Locations: U.S, lockstep

☆ Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
▼ + stars: | 2024-04-24 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Swiss pharmaceutical company Roche on Wednesday reported a modest uptick in first-quarter sales, even as waning demand for its Covid-19 products continued to weigh on the company. Sales were up 2% at constant exchange rates, led by stronger demand for Roche's newer medicines and diagnostics, the company said. Excluding Covid-19 products, sales were up 7%. But sales tightened when reported in the company's local currency, down 6% off the back of a strong Swiss franc. Roche CEO Thomas Schinecker on Wednesday confirmed the company's 2024 outlook, saying it was largely out of the woods following a post-Covid-19 slump.

Persons: Roche, Thomas Schinecker, Schinecker Organizations: Roche, AG, Wednesday, Reuters Locations: Basel, Switzerland, Swiss

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
▼ + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.

Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration

With interest rate uncertainty on the rise across the market, it may be time to buy stocks with a demonstrated history of low volatility. The Cboe Volatility Index — a yardstick of expected market volatility — briefly rose above 21 on Friday, its highest level since last October. The insurance stock currently has a 5-year beta of 0.54 relative to the S & P 500, and a price volatility score of 6.28. With a 5-year beta of 0.78 versus the S & P 500 and a 5-year price volatility score of 6.50, medical equipment maker Boston Scientific also turned up on the screen. Compared to the S & P 500, Merck's 5-year beta comes in at 0.39, while its 5-year price volatility scores a 6.06.

Persons: Joanne Wuensch Organizations: CNBC Pro, Boston Scientific, Citigroup, Boston, Pharmaceutical, Merck, Food, NextEra Energy Locations: UnitedHealth

☆ Martin Wygod, a Winner on Wall Street and the Racetrack, Dies at 84
▼ + stars: | 2024-04-20 | by ( Sam Roberts | ) www.nytimes.com time to read: +1 min

Martin J. Wygod, a Wall Street whiz who graduated from walking horses after races to owning and breeding championship thoroughbreds when he made millions from investing in online companies that sold pharmaceuticals by mail and pruned medical paperwork, died on April 12 in San Diego. His daughter, Emily Bushnell, said he died in a hospital from complications of lung disease. Raised near two racetracks in suburban New York and mentored by a software pioneer, an investor and a gambler, Mr. Wygod was said to have been the youngest managing partner of a New York Stock Exchange brokerage in the 1960s. The sale netted Mr. Wygod $250 million. “Marty Wygod made $6 billion for himself because he developed a data base.”

Persons: Martin J, Emily Bushnell, Wygod, ” Jan Buck, “ Marty Wygod Organizations: New York Stock Exchange, Merck, Princeton Group International, New York Times Locations: San Diego, New York

☆ Here’s what marijuana researchers have to say about 420 or ‘weed day’
▼ + stars: | 2024-04-20 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +12 min

CNN —It’s 420 or “weed day,” and people around the world will be paying homage to their favorite guilty pleasure: marijuana. “I worry when people are in an enclosed space because new data is beginning to show that secondhand marijuana smoke may be just as dangerous as the primary smoke,” Page said. “Approximately 3 in 10 people who use marijuana have marijuana use disorder,” according to the US Centers for Disease Control and Prevention. In fact, some parents told doctors they believed vaping marijuana was safer than tobacco, Boyd told CNN earlier via email. A cloud of marijuana smoke rises as a clock hits 4:20 p.m. during the Mile High 420 Festival in Denver on "weed day" in 2022.

Persons: CNN —, Dr, Beth Cohen, Cohen, “, ”, Robert Page II, ” Page, Weed, It’s, ’ ” Carol Boyd, Ann Arbor, Peter Grinspoon, ” Young, Sam Wang, Boyd, Grinspoon, Patrick T, Fallon, Nixon, ” Boyd, ” Grinspoon, ’ ”, Page Organizations: CNN, District of Columbia, University of California, University of Colorado Skaggs School of Pharmacy, Pharmaceutical Sciences, Center, Drugs, University of Michigan, US Centers for Disease Control, Prevention, CDC, Massachusetts General Hospital, Marijuana, Children’s Hospital, Yale Medicine, Drug, University of Colorado’s, Getty, University of Mississippi, US Drug, Administration Locations: United States, San Francisco, Colorado, Aurora, Ann, Boston, Children’s Hospital Colorado, Denver, AFP

☆ Friday, April 19, 2024: The Investing Club breaks down this consumer staple post-earnings
▼ + stars: | 2024-04-19 | by ( ) www.cnbc.com time to read: 1 min

Friday, April 19, 2024: The Investing Club breaks down this consumer staple post-earningsJim and Jeff give an earnings analysis on this consumer staple stock. They also talk about the potential tailwind for this pharmaceutical stock. Finally, they discuss the latest moves for this energy stock.

Persons: Jim, Jeff

☆ Bayer Leverkusen: Record 44-game unbeaten run brings to an end 31 years of hurt and ridicule
▼ + stars: | 2024-04-19 | by ( Ben Morse | ) edition.cnn.com time to read: +6 min

However, if you were a fan of German soccer club Bayer Leverkusen, little changed for you over those 31 years – there was just a lot of disappointment. Since winning the German Cup in 1993, Leverkusen relentlessly explored increasingly agonizing ways of spurning chances to win trophies. The current season has already reaped rewards in the form of the Bundesliga title, with potential domestic and European competition success transforming this into a season for the ages. Everybody was on the pitch this evening, everybody was crying.”After years being the butt of the joke, Leverkusen fans could finally spin the narrative. Leverkusen fans celebrated en masse on the pitch after winning the German league title.

Persons: ’, David Letterman ’, Xabi, Alonso, Mike Hewitt, ”, Schwarzroten, ‘ You’ll, Olaf Schmidt –, –, midfifelder, Jeremie Frimpong, Xabi Alonso, Lars Baron, Florian Wirtz’s wizardry, Deutscher Meister ’, ” Schmidt, ‘, Schmidt, Andreas Rentz, ” Uwe Schewiola Organizations: CNN, Chicago Bulls, NBA, The Bulls, Bayer Leverkusen, Basque, Bundesliga, Europa League, West Ham United, Getty, Real Madrid, ’, Olaf Schmidt – Leverkusen, CNN Sport, Bayern, Spain, Leverkusen, Bayern Munich, Bayer, Werder Bremen, Black, Reds, FC Kaiserslautern Locations: German, Europe, Real, London, Liverpool, Bayern Munich, Real Madrid, Germany, England, Spain, Italy, Tolosa, West Ham

☆ Loads of analysts cut their price targets on these 10 stocks ahead of earnings
▼ + stars: | 2024-04-18 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Analysts have lowered their expectations on several global stocks this week by cutting their price targets. The list of stocks includes auto stocks Tesla , Rivian and Aptiv , pharmaceutical firms Biogen and Novartis , energy companies EQT Corp and TotalEnergies , airline Deutsche Lufthansa and aerospace firm Boeing , and fast food giant McDonald's . The price target changes come ahead of the next earnings season covering the first quarter of this year. CNBC Pro screened for global stocks in the MSCI World index that have received price target downgrades over the past seven days and are yet to report earnings. Tesla Wall Street analysts from 15 firms downgraded their 12-month price targets for Tesla over the past week.

Persons: Elon Musk, Tesla's, Tesla, Stifel Nicholas, Johannes Braun, Marc Zeck, Samantha Subin, Michael Bloom Organizations: Novartis, EQT Corp, Deutsche Lufthansa, Boeing, CNBC Pro, Barclays, Lufthansa Locations: Stifel

Kam Ghaffarian, co-founder and chairman of Axiom Space Inc., speaks during an interview at the company's headquarters in Houston, Texas, U.S., on Friday, Jan. 14, 2022. IBX's Kam Ghaffarian wants to go even further: the stars. Ghaffarian has been instrumental in ushering in the new space economy, having co-founded and invested in a cadre of commercial space ventures. Unlike other high-profile billionaires building commercial space companies, Ghaffarian made his fortune through the space industry, and rather than focusing on access to space, he's leveraging those falling costs to build out infrastructure and business activities in space. Ghaffarian believes the space economy will be worth trillions of dollars — and sooner than many realize.

Persons: Kam Ghaffarian, Jeff Bezos, Richard Branson, Elon Musk, IBX's Kam Ghaffarian, CNBC's Morgan Brennan, Ghaffarian, Odysseus, he's, We've, Jeff, Bezos, we've, Morgan Brennan, it's Organizations: Space, International, Elon, Technologies, NASA, KBR, SpaceX Locations: Houston , Texas, U.S, Colorado Springs, Iran

☆ These are the 10 most overvalued stocks in the S&P 500
▼ + stars: | 2024-04-18 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Shares of these companies would be considered overvalued, meaning they're trading at a current price that is not justified by their P/E ratio. Super Micro Computer trades at a 32.9 forward P/E, which is 173% above the five-year average P/E of 12.1. Microchip Technology is trading 73% above its five-year average P/E ratio of 15.8, while Broadcom is trading at a 58% premium. Eli Lilly is another overvalued name, as the stock is trading at a 71% premium to its five-year average. Other expensive stocks included in the list include copper producer Freeport McMoRan , pharmaceutical company Bristol-Myers Squibb and Tyson Foods .

Persons: Dow, Eli Lilly, Mounjaro, Eli Lilly's, Myers Squibb Organizations: Nasdaq, CNBC, Computer, Broadcom, Technology, Micro Computer, Bristol, Myers, Tyson Foods Locations: Freeport

Search resuls for: "Pharmaceutical"

25 mentions found